Aqueous solutions are the primary dosage form designed for intravenous (IV) injection. Because anything entering a vein travels directly to the heart and lungs, only formulations that are completely free of large particles, sterile, and compatible with blood can be given this way. That narrows the list considerably compared to other injection routes, but several distinct dosage forms qualify.
Aqueous Solutions
A true solution, where the drug is fully dissolved in water or a water-based solvent, is the most common and most straightforward IV dosage form. The drug molecules are dispersed at the molecular level, so there is nothing solid that could block a blood vessel. Saline drips, dextrose infusions, and most emergency medications fall into this category. These solutions can be given as a rapid push (bolus) directly into a vein over seconds to minutes, or as a slow continuous infusion through an IV line over hours.
Some drugs don’t dissolve easily in plain water. To keep them in solution, manufacturers add co-solvents such as glycerin, polyethylene glycol, or sorbitol. Small amounts of surfactants like polysorbate 80 (used at concentrations up to about 0.65% in some IV antibody products) help stabilize the formulation. Multi-dose vials may also contain antimicrobial preservatives like benzyl alcohol or phenol to prevent contamination after the first use.
Powders for Reconstitution
Many drugs are not stable enough to sit in liquid form on a shelf for months. Instead, manufacturers package them as sterile dry powders, often freeze-dried (lyophilized). Right before administration, a healthcare provider mixes the powder with sterile water or saline to create a solution. Once reconstituted, the product is functionally identical to a ready-made aqueous solution and can be injected intravenously. Numerous antibiotics, chemotherapy agents, and clotting factors are supplied this way.
Lipid Emulsions
Lipid emulsions are a special case: tiny oil droplets suspended in water, stabilized so they behave almost like a solution in the bloodstream. These are used to deliver fats for nutrition (parenteral nutrition) and to carry drugs that won’t dissolve in water at all. The anesthetic propofol, for example, is marketed as an IV nanoemulsion (Diprivan).
The safety of a lipid emulsion depends entirely on how small the oil droplets are. The U.S. Pharmacopeia requires that the average droplet diameter stay below 500 nanometers, far smaller than a red blood cell. On top of that, the fraction of fat globules larger than 5 micrometers must be less than 0.05% of the total. Droplets above that size could physically block tiny capillaries in the lungs or other organs, so these limits are strictly enforced during manufacturing.
Liposomes and Nanoparticle Formulations
A growing number of IV drugs are delivered inside engineered nanostructures. Liposomes are hollow spheres made from the same type of fat molecules that form cell membranes. The drug sits inside the sphere or within the membrane wall, and the whole package circulates through the bloodstream until it reaches its target tissue. Dozens of liposomal products are approved for IV use, including formulations of the antifungal amphotericin B (AmBisome), the chemotherapy drug doxorubicin (Myocet), and a combination of daunorubicin and cytarabine (Vyxeos).
Beyond liposomes, other nanoparticle platforms used intravenously include solid-lipid nanoparticles, polymer-drug conjugates, and micellar dispersions. The chemotherapy agent paclitaxel, for instance, is available as an IV micellar formulation (Genexol). Iron-replacement therapies like ferumoxytol use dextran-coated iron oxide nanoparticles given by IV injection. In every case, the particle size is kept small enough to flow freely through capillaries without causing blockages.
Why Suspensions Are Not Given Intravenously
A suspension contains solid drug particles that don’t dissolve, just float in the liquid. Suspensions are commonly injected into muscle or under the skin, where the body can slowly absorb the particles. Injecting those same particles into a vein is dangerous. Solid particles larger than a few micrometers can physically wedge into the tiny arterioles and capillaries of the lungs, brain, or kidneys. This mechanical blockage cuts off blood flow to the tissue downstream, essentially causing microscopic areas of tissue death. The particles can also activate platelets and immune cells, triggering clots that make the obstruction worse.
Research on particulate contamination in IV fluids has documented outcomes ranging from silent lung granulomas (discovered only at autopsy) to severe respiratory failure and death. Patients who already have compromised circulation from trauma, surgery, or sepsis are especially vulnerable, because their microvessels are already under stress. This is why regulatory standards for IV products set strict particle count limits.
Particle and Purity Standards for IV Products
Every injectable product must meet particle count limits before it can be sold. For large-volume IV bags (over 100 mL), the standard allows no more than 25 particles per mL at 10 micrometers or larger, and no more than 3 particles per mL at 25 micrometers or larger. For small-volume injections (under 100 mL), the limit is 6,000 particles per container at 10 micrometers and 600 per container at 25 micrometers.
Sterility is non-negotiable for any IV product, but purity goes beyond just killing bacteria. Even dead bacteria release endotoxins, fragments of their cell walls that trigger fever and potentially fatal immune reactions. The FDA sets an endotoxin limit of 5 endotoxin units per kilogram of body weight per hour for IV drugs. Manufacturing processes include specific testing to confirm every batch falls below this threshold.
Bolus Versus Continuous Infusion
The same IV-compatible dosage form can be delivered in different ways depending on clinical need. A bolus injection pushes the full dose into the vein quickly, producing a rapid peak in blood concentration. This is useful in emergencies or when a fast response is needed. A continuous infusion delivers the drug slowly and steadily over hours through an IV drip, maintaining a more constant drug level in the blood and reducing sharp peaks that can increase side effects.
Both delivery methods use the same fundamental dosage forms: sterile solutions, reconstituted powders, or lipid emulsions. The choice between bolus and infusion depends on the drug’s properties and the clinical situation, not on the formulation itself. For some drugs, guidelines recommend starting with a bolus and switching to a continuous infusion if the initial response is inadequate.